

External Quality Assessment Scheme

Herpes simplex 1 and 2, antibodies Round 1, 2023

Specimens

Please find enclosed 3 human plasma or serum samples S001, S002 and S003, each 0.5 mL.

Caution

Quality control specimens derived from human blood must be handled with the same care as patient samples, i.e. as potential transmitters of serious diseases. The specimens are found to be HBsAg, HCVAb and HIVAgAb negative when tested with licensed reagents, but no known test method can offer complete assurance that the specimens will not transmit these or other infectious diseases.

Examinations

HSVAbG
HSVAbM
HSV1AbG
HSV2AbG

Storage and use

After arrival, the samples should be stored at +2...8 °C, and used as soon as possible, preferably within a week. The samples are ready for use. Analyse as patient samples.

Result reporting

Please enter the results and methods via LabScala (www.labscala.com). If you cannot find your instrument or reagent from the registry, please contact the EQA Coordinator. All reported examinations will be scored.

S001



S002



S003



2023-01-24

INSTRUCTIONS

Product no. 5555
LQ773523011-013/FI

Subcontracting: Sample pretesting

If the kit is incomplete or contains damaged specimens, please report immediately to info@labquality.fi.

The results should be reported no later than **February 16, 2023.**

The expected results of the round are published in LabScala in the View Reports section by February 20, 2023.

Inquiries

EQA Coordinator
Mira Saarinen
mira.h.saarinen@labquality.fi

Labquality Oy

Kumpulantie 15
FI-00520 HELSINKI
Finland

Tel. + 358 9 8566 8200
Fax + 358 9 8566 8280


info@labquality.fi
www.labquality.com



Client report

	No of participants	No of responded participants	Response percentage
Herpes simplex 1 and 2, antibodies, February, 1-2023	72	71	98.6 %

Summary




Summary	Own score	Max score	Own success rate	Difference	AVR success rate
Sample S001	4	4	100 %	2.8 %	97.2 %
Sample S002	4	4	100 %	2.8 %	97.2 %
Sample S003	4	4	100 %	11.5 %	88.5 %
Average:			100 %	5.7 %	94.3 %

History	Test nr.	Own success rate	Difference	AVR success rate
Round 2022-4	1-1	100 %	2.5 %	97.5 %
Round 2022-3	1-1	100 %	8.9 %	91.1 %
Round 2022-2	1-1	100 %	3.1 %	96.9 %
Round 2022-1	1-1	100 %	4.9 %	95.1 %
Round 2021-4	1-1	100 %	4.3 %	95.7 %
Round 2021-3	1-1	100 %	4.5 %	95.5 %
Round 2021-2	1-1	100 %	2.2 %	97.8 %
Round 2021-1	1-1	100 %	4.2 %	95.8 %


Sample S001

Sample S001 success rate




Sample S001 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	HSVAbG	-	-	-	-	100 %	41
	HSVAbM	-	-	-	-	100 %	46
	HSV1AbG	2	2	100 %	2.4 %	97.6 %	42
	HSV2AbG	2	2	100 %	8.2 %	91.8 %	49
	Further action	-	-	-	-	-	4
	Total:	4	4	100 %	2.8 %	97.2 %	182


Sample S001 HSVAbG




Sample S001 HSVAbM



Sample S001 HSV1AbG



Sample S001 HSV2AbG



HSVAbG	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	Positive		41		-				100 %
		DiaSorin LIAISON HSV-1/2 IgG assay		30					
		Diesse Chorus HERPES SIMPLEX 1+2 IgG		2					
		DRG Herpes Simplex 1+2 IgG		1					
		Euroimmun ELISA HSV IgG		1					
		In house EIA HSV		2					
		Novatec NovaLisa HSV 1+2 IgG ELISA		2					
		TestLine EIA HSV		1					
		TestLine EIA HSV 1+2 IgG		1					
		VirCell microbiol. Herpes Simplex VirClia		1					
	Total:		41		-	-	-	-	100 %

HSVAbM	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		46		-				100 %
		DiaSorin LIAISON HSV-1/2 IgM assay		24					
		Diesse Chorus HERPES SIMPLEX 1+2 IgM		2					
		Diesse Enzy-Well Line Herpes simplex 1+2 IgM		1					
		DRG Herpes Simplex 1+2 IgM		1					
		Euroimmun ELISA HSV IgM		2					
		Euroimmun immunoblot EUROLINE-WB HSV		1					
		Grifols Triturus EIA Herpes Simplex 1/2 Virus IgG/IgM		1					
		In house EIA HSV		2					
		Novatec NovaLisa HSV 1+2 IgM ELISA		2					
		Orgentec Alegria Anti-HSV-1/2 IgM		2					
		Shenzhen YHLO iFlash HSV 1+2 IgM		1					
		SNIBE Maglumi HSV-1/2 IgM		1					
		TestLine EIA HSV		1					
		TestLine EIA HSV 1+2 IgM		1					
		VirCell microbiol. Herpes Simplex VirClia		1					
		Virion/Serion ELISA HSV 1/2 IgM		1					
		Virotech HSV Screen IgG/IgM ELISA		2					
	Total:		46		-	-	-	-	100 %

OWN DEVICE: LIAISON XL

HSV1AbG	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		1		-				0 %
		Shenzhen YHLO iFlash HSV-1 IgG		1					
	<input checked="" type="radio"/> Positive		41		2	2	100 %	0 %	100 %
		Abbott Alinity HSV-1 IgG		3					
		Abbott ARCHITECT HSV-1 IgG		1					
		Bio-Rad BioPlex 2200 HSV-1 & HSV-2		3					
		<input checked="" type="radio"/> DiaSorin LIAISON HSV-1 IgG assay		13					
		Euroimmun Anti-Herpes simplex virus 1 ChLIA (IgG)		1					
		Euroimmun immunoblot EUROLINE-WB HSV		1					
		Focus Diagnostics HerpeSelect 1 and 2 Immunoblot IgG		2					
		Focus Diagnostics HerpeSelect 1 ELISA IgG		4					
		Grifols Triturus EIA Herpes Simplex 1 Virus IgG		1					
		In house EIA HSV		1					
		Novatec NovaLisa HSV 1 IgG ELISA		1					
		Orgentec Alegria Anti-HSV-1 IgG		2					
		Roche cobas HSV 1 IgG		4					

		TestLine EIA HSV		1					
		Vircell microbiol. Herpes Simplex VirClia		1					
		Virotech HSV 1 IgG ELISA		2					
	Total:		42		2	2	100 %	2.4 %	97.6 %


OWN DEVICE: LIAISON XL

HSV2AbG	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Negative		45		2	2	100 %	0 %	100 %
		Abbott Alinity HSV-2 IgG		3					
		Abbott ARCHITECT HSV-2 IgG		1					
		Bio-Rad BioPlex 2200 HSV-1 & HSV-2		4					
		<input checked="" type="radio"/> DiaSorin LIAISON HSV-2 IgG assay		17					
		Euroimmun Anti-Herpes simplex virus 2 ChLIA (IgG)		1					
		Euroimmun immunoblot EUROLINE-WB HSV		1					
		Focus Diagnostics HerpeSelect 1 and 2 Immunoblot IgG		2					
		Focus Diagnostics HerpeSelect 2 ELISA IgG		3					
		In house EIA HSV		1					
		Novatec NovaLisa HSV 2 IgG ELISA		1					
		Orgentec Alegria Anti-HSV-2 IgG		2					
		Roche cobas HSV 2 IgG		4					
		Shenzhen YHLO iFlash HSV-2 IgG		1					
		Vircell microbiol. Herpes Simplex VirClia		2					
		Virotech HSV 2 IgG ELISA		2					
	Borderline		1		-				0 %
		DiaSorin LIAISON HSV-2 IgG assay		1					
	Positive		3		-				0 %
		Focus Diagnostics HerpeSelect 2 ELISA IgG		1					
		Grifols Triturus EIA Herpes Simplex 2 Virus IgG		1					
		TestLine EIA HSV		1					
	Total:		49		2	2	100 %	8.2 %	91.8 %

Further action	Response	Response count	Own score	Max score	Own success rate	Difference	AVR success rate
	New sample is requested	1	-				-
	Referred to confirmation	1	-				-
	Referred to confirmation and a new sample is requested	2	-				-
	Total:	4	-	-	-	-	

Sample S002

Sample S002 success rate




Sample S002 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	HSVAbG	-	-	-	-	100 %	41
	HSVAbM	-	-	-	-	97.8 %	46
	HSV1AbG	2	2	100 %	7.1 %	92.9 %	42
	HSV2AbG	2	2	100 %	2 %	98 %	49
	Further action	-	-	-	-	-	4
	Total:	4	4	100 %	2.8 %	97.2 %	182

Sample S002 HSVAbG



Positive

Sample S002 HSVAbM




Negative Positive

Sample S002 HSV1AbG



Negative Positive

Sample S002 HSV2AbG



Negative Positive

HSVAbG	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	Positive		41		-				100 %
		DiaSorin LIAISON HSV-1/2 IgG assay		30					
		Diesse Chorus HERPES SIMPLEX 1+2 IgG		2					
		DRG Herpes Simplex 1+2 IgG		1					
		Euroimmun ELISA HSV IgG		1					
		In house EIA HSV		2					
		Novatec NovaLisa HSV 1+2 IgG ELISA		2					
		TestLine EIA HSV		1					
		TestLine EIA HSV 1+2 IgG		1					
		VirCell microbiol. Herpes Simplex VirClia		1					
	Total:		41		-	-	-	-	100 %

HSVAbM	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		45		-				100 %
		DiaSorin LIAISON HSV-1/2 IgM assay		24					
		Diesse Chorus HERPES SIMPLEX 1+2 IgM		2					
		Diesse Enzy-Well Line Herpes simplex 1+2 IgM		1					
		DRG Herpes Simplex 1+2 IgM		1					
		Euroimmun ELISA HSV IgM		2					
		Euroimmun immunoblot EUROLINE-WB HSV		1					
		Grifols Triturus EIA Herpes Simplex 1/2 Virus IgG/IgM		1					
		In house EIA HSV		2					
		Novatec NovaLisa HSV 1+2 IgM ELISA		2					
		Orgentec Alegria Anti-HSV-1/2 IgM		2					
		SNIBE Maglumi HSV-1/2 IgM		1					
		TestLine EIA HSV		1					
		TestLine EIA HSV 1+2 IgM		1					
		VirCell microbiol. Herpes Simplex VirClia		1					
		Virion/Serion ELISA HSV 1/2 IgM		1					
		Virotech HSV Screen IgG/IgM ELISA		2					
	Positive		1		-				0 %
		Shenzhen YHLO iFlash HSV 1+2 IgM		1					
	Total:		46		-	-	-	-	97.8 %

OWN DEVICE: LIAISON XL

HSV1AbG	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Negative		39		2	2	100 %	0 %	100 %
		Abbott Alinity HSV-1 IgG		3					
		Abbott ARCHITECT HSV-1 IgG		1					
		Bio-Rad BioPlex 2200 HSV-1 & HSV-2		3					
		<input checked="" type="radio"/> DiaSorin LIAISON HSV-1 IgG assay		13					
		Euroimmun Anti-Herpes simplex virus 1 ChLIA (IgG)		1					
		Focus Diagnostics HerpeSelect 1 and 2 Immunoblot IgG		2					
		Focus Diagnostics HerpeSelect 1 ELISA IgG		4					
		Grifols Triturus EIA Herpes Simplex 1 Virus IgG		1					
		In house EIA HSV		1					
		Novatec NovaLisa HSV 1 IgG ELISA		1					
		Orgentec Alegria Anti-HSV-1 IgG		2					
		Roche cobas HSV 1 IgG		4					
		VirCell microbiol. Herpes Simplex VirClia		1					
		Virotech HSV 1 IgG ELISA		2					

	Positive		3		-				0 %
		Euroimmun immunoblot EUROLINE-WB HSV		1					
		Shenzhen YHLO iFlash HSV-1 IgG		1					
		TestLine EIA HSV		1					
	Total:		42		2	2	100 %	7.1 %	92.9 %


OWN DEVICE: LIAISON XL

HSV2AbG	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		1		-				0 %
		Shenzhen YHLO iFlash HSV-2 IgG		1					
	<input checked="" type="radio"/> Positive		48		2	2	100 %	0 %	100 %
		Abbott Alinity HSV-2 IgG		3					
		Abbott ARCHITECT HSV-2 IgG		1					
		Bio-Rad BioPlex 2200 HSV-1 & HSV-2		4					
		<input checked="" type="radio"/> DiaSorin LIAISON HSV-2 IgG assay		18					
		Euroimmun Anti-Herpes simplex virus 2 ChLIA (IgG)		1					
		Euroimmun immunoblot EUROLINE-WB HSV		1					
		Focus Diagnostics HerpeSelect 1 and 2 Immunoblot IgG		2					
		Focus Diagnostics HerpeSelect 2 ELISA IgG		4					
		Grifols Triturus EIA Herpes Simplex 2 Virus IgG		1					
		In house EIA HSV		1					
		Novatec NovaLisa HSV 2 IgG ELISA		1					
		Orgentec Alegria Anti-HSV-2 IgG		2					
		Roche cobas HSV 2 IgG		4					
		TestLine EIA HSV		1					
		Vircell microbiol. Herpes Simplex VirClia		2					
		Virotech HSV 2 IgG ELISA		2					
	Total:		49		2	2	100 %	2 %	98 %

Further action	Response	Response count	Own score	Max score	Own success rate	Difference	AVR success rate
	New sample is requested	2	-				-
	Referred to confirmation	2	-				-
	Total:	4	-	-	-	-	


Sample S003

Sample S003 success rate




Sample S003 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	HSVAbG	-	-	-	-	92.7 %	41
	HSVAbM	-	-	-	-	63 %	46
	HSV1AbG	2	2	100 %	0 %	100 %	40
	HSV2AbG	2	2	100 %	0 %	100 %	47
	Further action	-	-	-	-	-	13
	Total:	4	4	100 %	11.5 %	88.5 %	187


Sample S003 HSVAbG




Sample S003 HSVAbM



Sample S003 HSV1AbG



Sample S003 HSV2AbG



HSVAbG	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		38		-				100 %
		DiaSorin LIAISON HSV-1/2 IgG assay		27					
		Diesse Chorus HERPES SIMPLEX 1+2 IgG		2					
		DRG Herpes Simplex 1+2 IgG		1					
		Euroimmun ELISA HSV IgG		1					
		In house EIA HSV		2					
		Novatec NovaLisa HSV 1+2 IgG ELISA		2					
		TestLine EIA HSV		1					
		TestLine EIA HSV 1+2 IgG		1					
		Vircell microbiol. Herpes Simplex VirClia		1					
	Positive		3		-				0 %
		DiaSorin LIAISON HSV-1/2 IgG assay		3					
	Total:		41		-	-	-	-	92.7 %

HSVAbM	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		29		-				100 %
		DiaSorin LIAISON HSV-1/2 IgM assay		7					
		Diesse Chorus HERPES SIMPLEX 1+2 IgM		2					
		Diesse Enzy-Well Line Herpes simplex 1+2 IgM		1					
		DRG Herpes Simplex 1+2 IgM		1					
		Euroimmun ELISA HSV IgM		2					
		Euroimmun immunoblot EUROLINE-WB HSV		1					
		Grifols Triturus EIA Herpes Simplex 1/2 Virus IgG/IgM		1					
		In house EIA HSV		2					
		Novatec NovaLisa HSV 1+2 IgM ELISA		2					
		Orgentec Alegria Anti-HSV-1/2 IgM		2					
		Shenzhen YHLO iFlash HSV 1+2 IgM		1					
		SNIBE Maglumi HSV-1/2 IgM		1					
		TestLine EIA HSV		1					
		TestLine EIA HSV 1+2 IgM		1					
		Vircell microbiol. Herpes Simplex VirClia		1					
		Virion/Serion ELISA HSV 1/2 IgM		1					
		Virotech HSV Screen IgG/IgM ELISA		2					
	Borderline		10		-				0 %
		DiaSorin LIAISON HSV-1/2 IgM assay		10					
	Positive		7		-				0 %
		DiaSorin LIAISON HSV-1/2 IgM assay		7					
	Total:		46		-	-	-	-	63 %

OWN DEVICE: LIAISON XL

HSV1AbG	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Negative		40		2	2	100 %	0 %	100 %
		Abbott Alinity HSV-1 IgG		3					
		Abbott ARCHITECT HSV-1 IgG		1					
		Bio-Rad BioPlex 2200 HSV-1 & HSV-2		3					
		<input checked="" type="radio"/> DiaSorin LIAISON HSV-1 IgG assay		13					
		Euroimmun Anti-Herpes simplex virus 1 ChLIA (IgG)		1					
		Euroimmun immunoblot EUROLINE-WB HSV		1					
		Focus Diagnostics HerpeSelect 1 and 2 Immunoblot IgG		2					
		Focus Diagnostics HerpeSelect 1 ELISA IgG		2					
		Grifols Triturus EIA Herpes Simplex 1 Virus IgG		1					

	In house EIA HSV		1						
	Novatec NovaLisa HSV 1 IgG ELISA		1						
	Orgentec Alegria Anti-HSV-1 IgG		2						
	Roche cobas HSV 1 IgG		4						
	Shenzhen YHLO iFlash HSV-1 IgG		1						
	TestLine EIA HSV		1						
	Vircell microbiol. Herpes Simplex VirClia		1						
	Virotech HSV 1 IgG ELISA		2						
	Total:		40		2	2	100 %	0 %	100 %

OWN DEVICE: LIAISON XL

HSV2AbG	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Negative		47		2	2	100 %	0 %	100 %
		Abbott Alinity HSV-2 IgG		3					
		Abbott ARCHITECT HSV-2 IgG		1					
		Bio-Rad BioPlex 2200 HSV-1 & HSV-2		4					
		<input checked="" type="radio"/> DiaSorin LIAISON HSV-2 IgG assay		18					
		Euroimmun Anti-Herpes simplex virus 2 ChLIA (IgG)		1					
		Euroimmun immunoblot EUROLINE-WB HSV		1					
		Focus Diagnostics HerpeSelect 1 and 2 Immunoblot IgG		2					
		Focus Diagnostics HerpeSelect 2 ELISA IgG		2					
		Grifols Triturus EIA Herpes Simplex 2 Virus IgG		1					
		In house EIA HSV		1					
		Novatec NovaLisa HSV 2 IgG ELISA		1					
		Orgentec Alegria Anti-HSV-2 IgG		2					
		Roche cobas HSV 2 IgG		4					
		Shenzhen YHLO iFlash HSV-2 IgG		1					
		TestLine EIA HSV		1					
		Vircell microbiol. Herpes Simplex VirClia		2					
		Virotech HSV 2 IgG ELISA		2					
	Total:		47		2	2	100 %	0 %	100 %

Further action	Response	Response count	Own score	Max score	Own success rate	Difference	AVR success rate
	New sample is requested	7	-				-
	Referred to confirmation and a new sample is requested	6	-				-
	Total:	13	-	-	-	-	

Report Info

PARTICIPANTS

Altogether 72 laboratories from 23 countries participated in this EQA round.

REPORT INFO

The results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green color and laboratory's own result with a black radio button . In the scoring report you will find summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodic counts in the tables. If you have not reported any results you will get a note: "You have not responded in time, only global report is available".

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

SCORING

The round is scored based on test results when 60% or more of the participants report the expected result and when at least three results are reported. The following general rules are applied:

Correct/expected test result 2/2 points
False/deviating test result 0/2 points


The performance of the laboratory is assessed by the Own success rate (%). The target is 100%. The examination-specific scores obtained by the laboratory in the round are converted to Own success rate per sample (scores/maximum scores*100). The Laboratory's Own success rate is the average of the sample success rates.

The success rate for the entire round (AVR success rate) is calculated from the total number of scores given to the results per sample (all scores/maximum scores*100). The AVG success rate of the entire round is the average of the sample success rates. The difference in the Laboratory's Own success rate (%) to the corresponding numbers for the entire round is shown in the table.

GLOBAL REPORT

	No of participants	No of responded participants	Response percentage
Herpes simplex 1 and 2, antibodies, February, 1-2023	72	71	98.6 %


Summary



Summary	AVR success rate
Sample S001	97.2 %
Sample S002	97.2 %
Sample S003	88.5 %
Average:	94.3 %


Sample S001

Sample S001 success rate




Sample S001 results	Responded	AVR success rate	Count
	HSVAbG	100 %	41
	HSVAbM	100 %	46
	HSV1AbG	97.6 %	42
	HSV2AbG	91.8 %	49
	Further action	-	4
	Total:	97.2 %	182


Sample S001 HSVAbG




Sample S001 HSVAbM



Sample S001 HSV1AbG



Sample S001 HSV2AbG



HSVAbG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Positive		41		100 %	2
		DiaSorin LIAISON HSV-1/2 IgG assay		30		
		Diesse Chorus HERPES SIMPLEX 1+2 IgG		2		
		DRG Herpes Simplex 1+2 IgG		1		
		Euroimmun ELISA HSV IgG		1		
		In house EIA HSV		2		
		Novatec NovaLisa HSV 1+2 IgG ELISA		2		
		TestLine EIA HSV		1		
		TestLine EIA HSV 1+2 IgG		1		
		Vircell microbiol. Herpes Simplex VirClia		1		
	Total:		41		100 %	

HSVAbM	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		46		100 %	2
		DiaSorin LIAISON HSV-1/2 IgM assay		24		
		Diesse Chorus HERPES SIMPLEX 1+2 IgM		2		
		Diesse Enzy-Well Line Herpes simplex 1+2 IgM		1		
		DRG Herpes Simplex 1+2 IgM		1		
		Euroimmun ELISA HSV IgM		2		
		Euroimmun immunoblot EUROLINE-WB HSV		1		
		Grifols Triturus EIA Herpes Simplex 1/2 Virus IgG/IgM		1		
		In house EIA HSV		2		
		Novatec NovaLisa HSV 1+2 IgM ELISA		2		
		Orgentec Alegria Anti-HSV-1/2 IgM		2		
		Shenzhen YHLO iFlash HSV 1+2 IgM		1		
		SNIBE Maglumi HSV-1/2 IgM		1		
		TestLine EIA HSV		1		
		TestLine EIA HSV 1+2 IgM		1		
		Vircell microbiol. Herpes Simplex VirClia		1		
		Virion/Serion ELISA HSV 1/2 IgM		1		
		Virotech HSV Screen IgG/IgM ELISA		2		
	Total:		46		100 %	

HSV1AbG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		1		0 %	0
		Shenzhen YHLO iFlash HSV-1 IgG		1		
	Positive		41		100 %	2
		Abbott Alinity HSV-1 IgG		3		
		Abbott ARCHITECT HSV-1 IgG		1		
		Bio-Rad BioPlex 2200 HSV-1 & HSV-2		3		
		DiaSorin LIAISON HSV-1 IgG assay		13		
		Euroimmun Anti-Herpes simplex virus 1 ChLIA (IgG)		1		
		Euroimmun immunoblot EUROLINE-WB HSV		1		
		Focus Diagnostics HerpeSelect 1 and 2 Immunoblot IgG		2		
		Focus Diagnostics HerpeSelect 1 ELISA IgG		4		
		Grifols Triturus EIA Herpes Simplex 1 Virus IgG		1		
		In house EIA HSV		1		
		Novatec NovaLisa HSV 1 IgG ELISA		1		
		Orgentec Alegria Anti-HSV-1 IgG		2		
		Roche cobas HSV 1 IgG		4		
		TestLine EIA HSV		1		
		Vircell microbiol. Herpes Simplex VirClia		1		
		Virotech HSV 1 IgG ELISA		2		
	Total:		42		97.6 %	


HSV2AbG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		45		100 %	2
		Abbott Alinity HSV-2 IgG		3		
		Abbott ARCHITECT HSV-2 IgG		1		
		Bio-Rad BioPlex 2200 HSV-1 & HSV-2		4		

		DiaSorin LIAISON HSV-2 IgG assay		17		
		Euroimmun Anti-Herpes simplex virus 2 ChLIA (IgG)		1		
		Euroimmun immunoblot EUROLINE-WB HSV		1		
		Focus Diagnostics HerpeSelect 1 and 2 Immunoblot IgG		2		
		Focus Diagnostics HerpeSelect 2 ELISA IgG		3		
		In house EIA HSV		1		
		Novatec NovaLisa HSV 2 IgG ELISA		1		
		Orgentec Alegria Anti-HSV-2 IgG		2		
		Roche cobas HSV 2 IgG		4		
		Shenzhen YHLO iFlash HSV-2 IgG		1		
		Vircell microbiol. Herpes Simplex VirClia		2		
		Virotech HSV 2 IgG ELISA		2		
	Borderline		1		0 %	0
		DiaSorin LIAISON HSV-2 IgG assay		1		
	Positive		3		0 %	0
		Focus Diagnostics HerpeSelect 2 ELISA IgG		1		
		Grifols Triturus EIA Herpes Simplex 2 Virus IgG		1		
		TestLine EIA HSV		1		
	Total:		49		91.8 %	

Further action	Response	Response count	AVR success rate	Response Score
	New sample is requested	1	-	-
	Referred to confirmation	1	-	-
	Referred to confirmation and a new sample is requested	2	-	-
	Total:	4		

Sample S002

Sample S002 success rate




Sample S002 results	Responded	AVR success rate	Count
	HSVAbG	100 %	41
	HSVAbM	97.8 %	46
	HSV1AbG	92.9 %	42
	HSV2AbG	98 %	49
	Further action	-	4
	Total:	97.2 %	182

Sample S002 HSVAbG



Positive

Sample S002 HSVAbM




Negative Positive

Sample S002 HSV1AbG



Negative Positive

Sample S002 HSV2AbG



Negative Positive

HSVAbG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Positive		41		100 %	2
		DiaSorin LIAISON HSV-1/2 IgG assay		30		
		Diesse Chorus HERPES SIMPLEX 1+2 IgG		2		
		DRG Herpes Simplex 1+2 IgG		1		
		Euroimmun ELISA HSV IgG		1		
		In house EIA HSV		2		
		Novatec NovaLisa HSV 1+2 IgG ELISA		2		
		TestLine EIA HSV		1		
		TestLine EIA HSV 1+2 IgG		1		
		Vircell microbiol. Herpes Simplex VirClia		1		
	Total:		41		100 %	

HSVAbM	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		45		100 %	2
		DiaSorin LIAISON HSV-1/2 IgM assay		24		
		Diesse Chorus HERPES SIMPLEX 1+2 IgM		2		
		Diesse Enzy-Well Line Herpes simplex 1+2 IgM		1		
		DRG Herpes Simplex 1+2 IgM		1		
		Euroimmun ELISA HSV IgM		2		
		Euroimmun immunoblot EUROLINE-WB HSV		1		
		Grifols Triturus EIA Herpes Simplex 1/2 Virus IgG/IgM		1		
		In house EIA HSV		2		
		Novatec NovaLisa HSV 1+2 IgM ELISA		2		
		Orgentec Alegria Anti-HSV-1/2 IgM		2		
		SNIBE Maglumi HSV-1/2 IgM		1		
		TestLine EIA HSV		1		
		TestLine EIA HSV 1+2 IgM		1		
		Vircell microbiol. Herpes Simplex VirClia		1		
		Virion/Serion ELISA HSV 1/2 IgM		1		
		Virotech HSV Screen IgG/IgM ELISA		2		
	Positive		1		0 %	0
		Shenzhen YHLO iFlash HSV 1+2 IgM		1		
	Total:		46		97.8 %	

HSV1AbG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		39		100 %	2
		Abbott Alinity HSV-1 IgG		3		
		Abbott ARCHITECT HSV-1 IgG		1		
		Bio-Rad BioPlex 2200 HSV-1 & HSV-2		3		
		DiaSorin LIAISON HSV-1 IgG assay		13		
		Euroimmun Anti-Herpes simplex virus 1 ChLIA (IgG)		1		
		Focus Diagnostics HerpeSelect 1 and 2 Immunoblot IgG		2		
		Focus Diagnostics HerpeSelect 1 ELISA IgG		4		
		Grifols Triturus EIA Herpes Simplex 1 Virus IgG		1		
		In house EIA HSV		1		
		Novatec NovaLisa HSV 1 IgG ELISA		1		
		Orgentec Alegria Anti-HSV-1 IgG		2		
		Roche cobas HSV 1 IgG		4		
		Vircell microbiol. Herpes Simplex VirClia		1		
		Virotech HSV 1 IgG ELISA		2		
	Positive		3		0 %	0
		Euroimmun immunoblot EUROLINE-WB HSV		1		
		Shenzhen YHLO iFlash HSV-1 IgG		1		
		TestLine EIA HSV		1		
	Total:		42		92.9 %	


HSV2AbG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		1		0 %	0
		Shenzhen YHLO iFlash HSV-2 IgG		1		
	Positive		48		100 %	2

	Abbott Alinity HSV-2 IgG		3		
	Abbott ARCHITECT HSV-2 IgG		1		
	Bio-Rad BioPlex 2200 HSV-1 & HSV-2		4		
	DiaSorin LIAISON HSV-2 IgG assay		18		
	Euroimmun Anti-Herpes simplex virus 2 ChLIA (IgG)		1		
	Euroimmun immunoblot EUROLINE-WB HSV		1		
	Focus Diagnostics HerpeSelect 1 and 2 Immunoblot IgG		2		
	Focus Diagnostics HerpeSelect 2 ELISA IgG		4		
	Grifols Triturus EIA Herpes Simplex 2 Virus IgG		1		
	In house EIA HSV		1		
	Novatec NovaLisa HSV 2 IgG ELISA		1		
	Orgentec Alegria Anti-HSV-2 IgG		2		
	Roche cobas HSV 2 IgG		4		
	TestLine EIA HSV		1		
	Vircell microbiol. Herpes Simplex VirClia		2		
	Virotech HSV 2 IgG ELISA		2		
	Total:		49		98 %

Further action	Response	Response count	AVR success rate	Response Score
	New sample is requested	2	-	-
	Referred to confirmation	2	-	-
	Total:	4		


Sample S003

Sample S003 success rate




Sample S003 results	Responded	AVR success rate	Count
	HSVAbG	92.7 %	41
	HSVAbM	63 %	46
	HSV1AbG	100 %	40
	HSV2AbG	100 %	47
	Further action	-	13
	Total:	88.5 %	187


Sample S003 HSVAbG




Sample S003 HSVAbM



Sample S003 HSV1AbG



Sample S003 HSV2AbG



HSVAbG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		38		100 %	2
		DiaSorin LIAISON HSV-1/2 IgG assay		27		
		Diesse Chorus HERPES SIMPLEX 1+2 IgG		2		
		DRG Herpes Simplex 1+2 IgG		1		
		Euroimmun ELISA HSV IgG		1		
		In house EIA HSV		2		
		Novatec NovaLisa HSV 1+2 IgG ELISA		2		
		TestLine EIA HSV		1		
		TestLine EIA HSV 1+2 IgG		1		
		Vircell microbiol. Herpes Simplex VirClia		1		
	Positive		3		0 %	0
		DiaSorin LIAISON HSV-1/2 IgG assay		3		
	Total:		41		92.7 %	

HSVAbM	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		29		100 %	2
		DiaSorin LIAISON HSV-1/2 IgM assay		7		
		Diesse Chorus HERPES SIMPLEX 1+2 IgM		2		
		Diesse Enzy-Well Line Herpes simplex 1+2 IgM		1		
		DRG Herpes Simplex 1+2 IgM		1		
		Euroimmun ELISA HSV IgM		2		
		Euroimmun immunoblot EUROLINE-WB HSV		1		
		Grifols Triturus EIA Herpes Simplex 1/2 Virus IgG/IgM		1		
		In house EIA HSV		2		
		Novatec NovaLisa HSV 1+2 IgM ELISA		2		
		Orgentec Alegria Anti-HSV-1/2 IgM		2		
		Shenzhen YHLO iFlash HSV 1+2 IgM		1		
		SNIBE Maglumi HSV-1/2 IgM		1		
		TestLine EIA HSV		1		
		TestLine EIA HSV 1+2 IgM		1		
		Vircell microbiol. Herpes Simplex VirClia		1		
		Virion/Serion ELISA HSV 1/2 IgM		1		
		Virotech HSV Screen IgG/IgM ELISA		2		
	Borderline		10		0 %	0
		DiaSorin LIAISON HSV-1/2 IgM assay		10		
	Positive		7		0 %	0
		DiaSorin LIAISON HSV-1/2 IgM assay		7		
	Total:		46		63 %	

HSV1AbG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		40		100 %	2
		Abbott Alinity HSV-1 IgG		3		
		Abbott ARCHITECT HSV-1 IgG		1		
		Bio-Rad BioPlex 2200 HSV-1 & HSV-2		3		
		DiaSorin LIAISON HSV-1 IgG assay		13		
		Euroimmun Anti-Herpes simplex virus 1 ChLIA (IgG)		1		
		Euroimmun immunoblot EUROLINE-WB HSV		1		
		Focus Diagnostics HerpeSelect 1 and 2 Immunoblot IgG		2		
		Focus Diagnostics HerpeSelect 1 ELISA IgG		2		
		Grifols Triturus EIA Herpes Simplex 1 Virus IgG		1		
		In house EIA HSV		1		
		Novatec NovaLisa HSV 1 IgG ELISA		1		
		Orgentec Alegria Anti-HSV-1 IgG		2		
		Roche cobas HSV 1 IgG		4		
		Shenzhen YHLO iFlash HSV-1 IgG		1		
		TestLine EIA HSV		1		
		Vircell microbiol. Herpes Simplex VirClia		1		
		Virotech HSV 1 IgG ELISA		2		
	Total:		40		100 %	

HSV2AbG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		47		100 %	2
		Abbott Alinity HSV-2 IgG		3		
		Abbott ARCHITECT HSV-2 IgG		1		
		Bio-Rad BioPlex 2200 HSV-1 & HSV-2		4		
		DiaSorin LIAISON HSV-2 IgG assay		18		
		Euroimmun Anti-Herpes simplex virus 2 ChLIA (IgG)		1		
		Euroimmun immunoblot EUROLINE-WB HSV		1		
		Focus Diagnostics HerpeSelect 1 and 2 Immunoblot IgG		2		
		Focus Diagnostics HerpeSelect 2 ELISA IgG		2		
		Grifols Triturus EIA Herpes Simplex 2 Virus IgG		1		
		In house EIA HSV		1		
		Novatec NovaLisa HSV 2 IgG ELISA		1		
		Orgentec Alegria Anti-HSV-2 IgG		2		
		Roche cobas HSV 2 IgG		4		
		Shenzhen YHLO iFlash HSV-2 IgG		1		
		TestLine EIA HSV		1		
		Vircell microbiol. Herpes Simplex VirClia		2		
		Virotech HSV 2 IgG ELISA		2		
	Total:		47		100 %	

Further action	Response	Response count	AVR success rate	Response Score
	New sample is requested	7	-	-
	Referred to confirmation and a new sample is requested	6	-	-
	Total:	13		

Report Info

PARTICIPANTS

Altogether 72 laboratories from 23 countries participated in this EQA round.

REPORT INFO

The results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green color and laboratory's own result with a black radio button . In the scoring report you will find summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodic counts in the tables. If you have not reported any results you will get a note: "You have not responded in time, only global report is available".

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

SCORING

The round is scored based on test results when 60% or more of the participants report the expected result and when at least three results are reported. The following general rules are applied:

Correct/expected test result 2/2 points
False/deviating test result 0/2 points

The performance of the laboratory is assessed by the Own success rate (%). The target is 100%. The examination-specific scores obtained by the laboratory in the round are converted to Own success rate per sample (scores/maximum scores*100). The Laboratory's Own success rate is the average of the sample success rates.

The success rate for the entire round (AVR success rate) is calculated from the total number of scores given to the results per sample (all scores/maximum scores*100). The AVG success rate of the entire round is the average of the sample success rates. The difference in the Laboratory's Own success rate (%) to the corresponding numbers for the entire round is shown in the table.

External Quality Assessment Scheme

Herpes simplex 1 and 2, antibodies Round 1, 2023

Specimens

Samples of this EQA round were human plasma or serum, each of which originated from a single donor. Based on the pre-testing and the results obtained in the round, the samples were homogeneous, stable and suitable for the external quality assessment scheme. The materials were sent without temperature control packaging.

The expected results were as follows:

Sample S001 (LQ773523011)

HSVAbG	Positive
HSVAbM	Negative
HSV-1AbG	Positive
HSV-2AbG	Negative

Sample S002 (LQ773523012)

HSVAbG	Positive
HSVAbM	Negative
HSV-1AbG	Negative
HSV-2AbG	Positive

Sample S003 (LQ773523013)

HSVAbG	Negative
HSVAbM	Negative
HSV-1AbG	Negative
HSV-2AbG	Negative

Pre-test methods: A type-common HSV in-house IgG test and a commercial type specific HSV-1 and HSV-2 IgG antibody test. HSV IgM antibodies were pre-tested by an in-house test.

Report info

Please see the description of the data analysis on the last page of the laboratory-specific reports and global reports. It is important to read the Final report first, because it contains important information of the samples and results in each round.

Comments – Expert

Sample S001 was expected to be positive for HSV IgG and HSV-1 IgG antibodies and negative for HSV-2 IgG and HSV IgM antibodies. All reported HSV IgG and HSV IgM antibody results were as expected. One negative HSV-1 IgG result as well as three positive and one borderline HSV-1 IgG result were reported.

Sample S002 was expected to be positive for HSV IgG and HSV-2 IgG antibodies and negative for HSV-1 IgG and HSV IgM antibodies. All reported HSV IgG antibody results were as expected. One positive HSV IgM result, three positive HSV-1-IgG results and one negative HSV-2 IgG results were reported.

Sample S003 was expected to be negative for all analytes. All reported HSV-1 IgG and HSV-2 IgG results were as expected. Three positive HSV IgG results were reported. Also, seven positive and ten borderline HSV IgM antibody results were reported (using a commercial test provided by a same manufacturer). However, over 60 % consensus was achieved, and the sample was scored.

2023-03-03

FINAL REPORT

Product no. 5555

Subcontracting: Sample pretesting

Samples sent	2023-01-24
Round closed	2023-02-16
Expected results	2023-02-17
Final report	2023-03-03

Request for correction

Typing errors in laboratory's result forms are on laboratory's responsibility. Labquality accepts responsibility only for result processing. Requests must be notified by writing within three weeks from the date of this letter.

Authorized by

EQA Coordinator
Mira Saarinen
mira.h.saarinen@labquality.fi

Expert

Docent
Tytti Vuorinen,
TUCH, UTU, Turku, Finland

Labquality Oy

Kumpulantie 15
FI-00520 HELSINKI
Finland

Tel. + 358 9 8566 8200

Fax + 358 9 8566 8280

info@labquality.fi
www.labquality.com



The overall success rate for the round was 94.3%.

Exceptions in scoring

No exceptions.

End of report

Copyright © Labquality Oy

Labquality does not permit any reproduction for commercial purposes of any portion of the material subject to this copyright. Labquality prohibits any use of its name, or reference to Labquality EQA program, or material in this report in any advertising, brochures or other commercial publications. Labquality EQA data do not necessarily indicate the superiority of instruments, reagents, testing equipments or materials used by participating laboratories. Use of Labquality EQA data to suggest superiority or inferiority of equipments or materials may be deceptive and misleading. Proficiency test results are handled confidentially. Labquality will not issue any statements to third parties of the performance of laboratories in external quality assessment schemes unless otherwise agreed.